Literature DB >> 20533391

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.

Hans E Johnsen1, Martin Bøgsted, Tobias W Klausen, Peter Gimsing, Alexander Schmitz, Erik Kjaersgaard, Tina Damgaard, Pia Voss, Lene M Knudsen, Anne K Mylin, Johan Lanng Nielsen, Bo Björkstrand, Astrid Gruber, Stig Lenhoff, Kari Remes, Inger Marie Dahl, Kirsten Fogd, Karen Dybkaer.   

Abstract

BACKGROUND AND AIM: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma (MM) is still unclear and under evaluation. Further progress relies on multiparametric profiling of the neoplastic plasma cell (PC) compartment to provide an accurate image of the stage of differentiation. The primary aim of this study was to perform global analysis of CD expression on the PC compartment and subsequently to evaluate the prognostic impact. Secondary aims were to study the diagnostic and predictive impact. DESIGN AND METHODS: The design included a retrospective analysis of MFC data generated from diagnostic bone marrow (BM) samples of 109 Nordic patients included in clinical trials within NMSG. Whole marrow were analyzed by MFC for identification of end-stage CD45(-) /CD38(++) neoplastic PC and registered the relative numbers of events and mean fluorescence intensity (MFI) staining for CD19, CD20, CD27, CD28, CD38, CD44, CD45, CD56, and isotypes for cluster analysis.
RESULTS: The median MFC-PC number was 15%, and the median light microscopy (LM)-PC number was 35%. However, the numbers were significant correlated and the prognostic value with an increased relative risk (95% CI) of 3.1 (1.7-5.5) and 2.9 (1.4-6.2), P < 0.0003 and P < 0.004 of MFC-PC and LM-PC counts, respectively. Unsupervised clustering based on global MFI assessment on PC revealed two clusters based on CD expression profiling. Cluster I with high intensity for CD56, CD38, CD45, right-angle light-scatter signal (SSC), forward-angle light-scatter signal (FSC), and low for CD28, CD19, and a Cluster II, with low intensity of CD56, CD38, CD45, SSC, FSC, and high for CD28, CD19 with a median survival of 39 months and 19 months, respectively (P = 0.02).
CONCLUSIONS: The MFC analysis of MM BM samples produces diagnostic, prognostic, and predictive information useful in clinical practice, which will be prospectively validated within the European Myeloma Network (EMN). © 2010 International Clinical Cytometry Society.
Copyright © 2010 International Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533391     DOI: 10.1002/cyto.b.20523

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  7 in total

Review 1.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

2.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

3.  Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.

Authors:  Jens Peter Andersen; Martin Bøgsted; Karen Dybkær; Ulf-Henrik Mellqvist; Gareth J Morgan; Hartmut Goldschmidt; Meletios A Dimopoulos; Hermann Einsele; Jesús San Miguel; Antonio Palumbo; Pieter Sonneveld; Hans Erik Johnsen
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

4.  The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients.

Authors:  Funda Ceran; Mesude Falay; Simten Dağdaş; Gülsüm Özet
Journal:  Turk J Haematol       Date:  2017-03-08       Impact factor: 1.831

5.  Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.

Authors:  Alexander Schmitz; Rasmus Froberg Brøndum; Hans Erik Johnsen; Ulf-Henrik Mellqvist; Anders Waage; Peter Gimsing; Davine Hofste Op Bruinink; Vincent van der Velden; Bronno van der Holt; Markus Hansson; Niels Frost Andersen; Ulf Christian Frølund; Carsten Helleberg; Fredrik H Schjesvold; Lucia Ahlberg; Nina Gulbrandsen; Bjorn Andreasson; Birgitta Lauri; Einar Haukas; Julie Støve Bødker; Anne Stidsholt Roug; Martin Bøgsted; Marianne T Severinsen; Henrik Gregersen; Niels Abildgaard; Pieter Sonneveld; Karen Dybkær
Journal:  BMC Cancer       Date:  2022-02-05       Impact factor: 4.430

6.  Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.

Authors:  Young-Uk Cho; Chan-Jeoung Park; Seo-Jin Park; Hyun-Sook Chi; Seongsoo Jang; Sang Hyuk Park; Eul-Ju Seo; Dok Hyun Yoon; Jung-Hee Lee; Cheolwon Suh
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

7.  Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma.

Authors:  Hyoeun Shim; Joo Hee Ha; Hyewon Lee; Ji Yeon Sohn; Hyun Ju Kim; Hyeon-Seok Eom; Sun-Young Kong
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.